Abstract
The aim of the present study is to enhance the anticancer and biocompatibility performance of TiO2 and ZnO nanoparticles, and, ZnO-TiO2 and ZnO-TiO2/reduced graphene oxide nanocomposites, against two types of human cancer (HCT116) and normal (HUVCE) cells.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
